RxDoctor Payments Data

Amit Dhir

Adult Health · Baltimore, MDNPI 1518498021

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 82.5% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $42,580, more than ten times the $957 reported in 2021. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$97,052in general payments, 2019–2025

Across 315 payments — averaging $308.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$80K
  • Viiv Healthcare Company$17K
  • Janssen Products, LP$199
  • Theratechnologies Inc.$67
  • Merck$38
  • Johnson & Johnson$36
  • plus $28 from 1 others

What the payments were for

  • Consulting fees$11,61912%
  • Speaking & faculty fees$56,54358%
  • Travel & lodging$18,18619%
  • Food & beverage$10,47811%
  • Education$1990%
  • Other$280%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,052 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala272$1,044,546
JulucaDolutegravir/Rilpivirine55$183,865
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf20$89,732
TriumeqAbacavir/Dolutegravir/Lamivudi22$79,474
GenvoyaElviteg/Cob/Emtri/Tenof Alafen17$61,120
PrezcobixDarunavir/Cobicistat25$60,763
DescovyEmtricitabine/Tenofov Alafenam24$50,021
DovatoDolutegravir Sodium/Lamivudine11$32,216
JardianceEmpagliflozin16$20,046
EntrestoSacubitril/Valsartan11$11,359
Tresiba Flextouch U-200Insulin Degludec18$6,923
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$6,006
Bicillin L-APenicillin G Benzathine13$3,638
Fluticasone Propionate HfaFluticasone Propionate13$3,246
Qvar RedihalerBeclomethasone Dipropionate12$3,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$80,108$1,155,687313 claims
Viiv Healthcare CompanyJuluca, Triumeq, Dovato$16,576$295,55588 claims
Janssen Products, LPSymtuza$199$89,73220 claims
Johnson & JohnsonPrezcobix$36$60,76325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.

Other adult health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →